Persistent dyslipidemia in statin-treated patients: The focus on comprehensive lipid management survey in Swiss patients

Swiss Medical Weekly

Volumn 141, Issue MAY, 2011, Pages

  Sudano, Isabella ^a   Hess, Lorenzo ^b   Noll, Georg ^a   Arnet, Diana ^c  

^a Cardiovascular Centre Cardiology   (Switzerland)

^b Brunner and Hess Software AG   (Switzerland)

^c Merck Sharp and Dohme Chibret AG   (Switzerland)

Author keywords

Lipid profile; Residual cardiovascular risk; Statin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; BODY MASS; CARDIOLOGIST; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOCRINOLOGY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; OUTPATIENT; PHYSICIAN; PREVALENCE; SEX DIFFERENCE; SWITZERLAND; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; MIDDLE AGED; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEX FACTORS; SWITZERLAND; TRIGLYCERIDES;

EID: 79958200876     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13200     Document Type: Article

References (33)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22. (Pubitemid 28248586)
3. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-58. (Pubitemid 36398384)
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9. (Pubitemid 26338729)
6. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-30. (Pubitemid 35379733)
7. Kizer JR, Madias C, Wilner B, Vaughan CJ, Mushlin AI, Trushin P, et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol. 2010;105(9):1289-96.
8. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069-77.
9. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, and Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769-81.
10. Shah PK, Kaul S, Nilsson J, and Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001;104(19):2376-83. (Pubitemid 33049524)
11. Gotto AM, Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144(6 Suppl):S33-42.
12. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-10. (Pubitemid 47481452)
13. Assmann G and Sacks F, www.escardio.org. 2009.
14. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. (Pubitemid 39208455)
15. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15. (Pubitemid 19043669)
16. Devendra GP, Whitney EJ, and Krasuski RA. Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study. J Cardiovasc Pharmacol Ther. 15(4):380-3.
17. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, and Levy D. Relations of Lipid Concentrations to Heart Failure Incidence. The Framingham Heart Study. Circulation. 2009.
18. Hokanson JE and Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213-9. (Pubitemid 26266496)
19. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep. 2008;10(5):386-90.
20. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, and Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724-30. (Pubitemid 351221217)
21. Tan YY, Gast GC, and van der Schouw YT. Gender differences in risk factors for coronary heart disease. Maturitas. 65(2):149-60.
22. LaRosa JC. Lipids and cardiovascular disease: Do the findings and therapy apply equally to men and women? Women's Health Issues. 2005;2(2):102-13.
23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
24. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87. (Pubitemid 46924065)
25. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009.
26. Alberti KG, Zimmet P, and Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366(9491):1059-62. (Pubitemid 41338752)
27. Assmann G, Cullen P, and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105(3):310-5. (Pubitemid 34106178)
28. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24(17):1601-10. (Pubitemid 37012194)
29. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28(19):2375-414.
30. Statistik Bf, Von Generation zu Generation: Entwicklung der Todesursachen 1970 bis 2004. 2008, BFS: Neuchâtel.
31. Statistik Bf, Statistik der Todesursachen 2007. 2009, BFS: Neuchâtel.
32. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
33. Jones P, Kafonek S, Laurora I, and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-7. (Pubitemid 28182422)